Today: 5 February 2026
Subscribe
Browse Category

Biotech News News 21 January 2026 - 2 February 2026

IDEAYA Biosciences stock jumps as February Citi, Evercore fireside chats near

IDEAYA Biosciences stock jumps as February Citi, Evercore fireside chats near

New York, Feb 2, 2026, 13:20 ET — Regular session Shares of IDEAYA Biosciences climbed about 5% on Monday, lifted by a broad upswing in biotech stocks. Investors zeroed in on the company ahead of two executive presentations scheduled for February. IDEAYA is heading into a stretch where investors expect clearer updates on clinical milestones. The stock often moves decisively…
2 February 2026
····
Amgen stock price near $342: AMGN heads into earnings after Kyowa Kirin deal exit

Amgen stock price near $342: AMGN heads into earnings after Kyowa Kirin deal exit

New York, Feb 1, 2026, 16:47 (ET) — Market closed Amgen shares slipped roughly 0.3% to close at $341.88 on Friday, a small shift ahead of a hectic week for the stock following its decision to exit an eczema drug partnership. A recent filing revealed that Amgen will pull out of its collaboration with Kyowa Kirin Co., Ltd. on rocatinlimab,…
1 February 2026
······
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock

New York, February 1, 2026, 09:12 EST — Market closed ImmunityBio shares (IBRX) ended Friday roughly 6% higher, closing at $6.25. That stands out as the S&P 500 tracker SPY dipped around 0.4%, and the Nasdaq 100 tracker QQQ dropped about 1.2%. The stock fluctuated between $5.68 and $6.45, with trading volume hitting close to 29.5 million shares. U.S. markets…
1 February 2026
·····
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX

New York, January 30, 2026, 15:23 EST — Regular session. ImmunityBio shares rose nearly 6% on Friday, clawing back from an early dip, as traders weighed fresh scrutiny tied to the drugmaker’s communications with the U.S. Food and Drug Administration. The stock was up 35 cents at $6.26, after trading between $5.68 and $6.45 on the day, on the Nasdaq.…
30 January 2026
·····
ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

ImmunityBio (IBRX) stock slides after glioblastoma update — here’s what investors watch next week

New York, Jan 24, 2026, 07:11 (EST) — Market closed ImmunityBio (NASDAQ: IBRX) shares closed Friday 12.1% lower at $6.45, after fluctuating between $7.86 and $6.44 during the session. The cancer immunotherapy firm saw roughly 76 million shares change hands. The decline comes just before next week as Wall Street shows renewed interest: On Thursday, BTIG lifted its price target…
24 January 2026
····
Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

Gilead stock jumps again as Trodelvy-Keytruda breast cancer data lands in NEJM

New York, Jan 23, 2026, 19:39 EST — After-hours Gilead Sciences shares climbed 3.65%, closing at $135.93 on Friday. The stock gained momentum after fresh breast cancer data refocused attention on the company’s oncology efforts. (Yahoo Finance) Gilead announced that full Phase 3 data from the ASCENT-04/KEYNOTE-D19 trial have been published in the New England Journal of Medicine. The study…
24 January 2026
····
Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

Cabaletta Bio stock jumps 11% premarket after insider buying cluster hits the tape

New York, January 22, 2026, 08:14 (ET) — Premarket Cabaletta Bio shares climbed roughly 11% in premarket trading Thursday, following a nearly 7% gain the previous day, fueled by a series of insider-buying reports. The stock was last indicated at $2.60, up from Wednesday’s close of $2.34. (Investing) This surge in buying is significant because Cabaletta is a small, cash-burning…
22 January 2026
·····
RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus

RAPT stock hovers near $58 as GSK buyout puts tender offer clock in focus

New York, Jan 21, 2026, 12:09 EST — Regular session. RAPT Therapeutics (RAPT.O) held steady on Wednesday, trading around $57.60 midday on Nasdaq. The shares ticked up just 0.05% during the session. After Tuesday’s sharp reprice, the shares are trading more like a deal spread than a high-flying biotech stock. That matters because what’s next largely boils down to routine…
21 January 2026
·····
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

New York, January 21, 2026, 08:47 EST — Premarket ImmunityBio’s stock dropped 5.9% to $6.10 in premarket trading Wednesday. The move followed the company’s announcement of a meeting with the U.S. Food and Drug Administration to discuss a possible resubmission of its bladder-cancer treatment, ANKTIVA. (MarketScreener) This move is significant because the FDA rejected ImmunityBio’s application last year to expand…
21 January 2026
·····
ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

New York, January 20, 2026, 20:22 ET — The market has closed. Shares of ImmunityBio, listed on Nasdaq, surged Tuesday following news that U.S. regulators outlined a potential path for the company to pursue an expanded bladder cancer indication for its drug ANKTIVA. The stock closed up 17.7% at $6.48, after trading between $4.94 and $7.97 on heavy volume. (Business…
21 January 2026
·····
Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

Corvus Pharmaceuticals stock surges 167% on eczema drug data as $150 million offering kicks off

New York, Jan 20, 2026, 19:13 ET — After-hours Corvus Pharmaceuticals shares surged over threefold on Tuesday following fresh data release on its experimental eczema pill. The biotech also announced plans to raise $150 million through an underwritten stock offering. After-hours trading saw the stock surge roughly 167% to $21.41, with about 84 million shares changing hands. This move matters…
21 January 2026
·····
RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

RAPT Therapeutics stock jumps 64% as GSK agrees $2.2 billion takeover at $58 a share

NEW YORK, Jan 20, 2026, 18:51 EST — After-hours Rapt Therapeutics (NASDAQ: RAPT) surged roughly 64% to $57.57 in after-hours trading Tuesday following news that Britain’s GSK will acquire the U.S. biotech. GSK’s $58-a-share cash bid values the deal at about a 65% premium over Monday’s close. This is the first big move by CEO Luke Miels, who just took…
21 January 2026
·····
1 2 3 … 12

Stock Market Today

  • TISE Sets Record with 1,140 New Listings in 2025, Market Value Hits £797 Billion
    February 5, 2026, 6:02 AM EST. The International Stock Exchange (TISE), owned by Miami International Holdings (NYSE: MIAX), recorded a 19.7% rise in new listings during 2025, reaching 1,140 securities. This boosted total listings to 4,818, up 7.4% year-on-year, with a market value of £797 billion, a 12.6% increase. TISE reported substantial gains in private equity debt, high yield bonds, and securitization bonds. Notably, high yield bond listings surged 74.6%. TISE also expanded its Equity Listing Rules for Specialist Companies and became the largest market for UK REITs, with 41 listed. Sustainable finance listings grew by 25.3% in value, reaching £32.2 billion. Issuers hailed from 38 territories, with the UK and EU leading new business sources. The results affirm TISE's status as a key European venue for bond listings aimed at qualified investors.
Go toTop